Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea

According to data from a recent retrospective cohort study of older patients with classical Philadelphia chromosome-negative MPNs, the cumulative incidence probability of secondary malignancies was 19.88% (95% CI, 17.16%-22.75%) among those who were treated with hydroxyurea and 22.31% (95% CI, 17.51%-27.47%) among those who did not, respectively (Gray’s test, P < .01). No significant differences were found in the incidence of solid or hematologic secondary malignancies, including AML/MDS (HR, 1.33; 95% CI, 0.77-2.29; P = .30).